Table 2.

Primary and key secondary outcomes ITT population

Endpoint	n	Responders, % (95% CI)	Adjusted % difference (95% CI)	Nominal P value
EASI 75 at week 16
Placebo	34	11.8% (0.9–22.6%)
Risankizumab 150 mg	69	24.6% (14.5–34.8%)	13.0% (–1.7 to 27.7%)	0.084
Risankizumab 300 mg	69	21.7% (12.0–31.5%)	10.0% (–4.6 to 24.6%)	0.179
vIGA-AD 0/1 with ≥ 2-point reduction from baseline at week 16
Placebo	34	5.9% (0.0–13.8%)
Risankizumab 150 mg	69	14.5% (6.2–22.8%)	8.7% (–2.5 to 20.0%)	0.129
Risankizumab 300 mg	69	5.8% (0.3–11.3%)	0.0% (–9.4 to 9.4%)	0.994
WP-NRS with ≥ 4-point reduction from baseline at week 16
Placebo	33	0.0
Risankizumab 150 mg	66	13.6% (5.4–21.9%)	13.7% (5.4–22.1%)	0.001
Risankizumab 300 mg	66	15.2% (6.5–23.8%)	15.3% (6.6–24.0%)	< 0.001

EASI 75 ≥ 75% reduction from baseline in Eczema Area and Severity Index, ITT intent to treat, vIGA-AD Validated Investigator Global Assessment for Atopic Dermatitis, WP-NRS Worst Pruritus Numeric Rating Scale